Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Flot.bio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Flot.bio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Fabrice Chouraqui, Pharming 🇳🇱 | Transgenic Rabbits, Rare Diseases | E43

54:48
 
Share
 

Manage episode 514941053 series 3470295
Content provided by Flot.bio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Flot.bio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

We travel to the offices of Pharming Group in Leiden, the Netherlands, to chat with the newcomer CEO Fabrice Chouraqui.

Fabrice discusses the fascinating history of Pharming, with its first commercial drug RUCONEST produced in the milk of transgenic rabbits. He also talks about the growth of Pharming from a protein therapy-focused biotech into a European multi-asset heavyweight, with a market cap of at least €800 million.

⭐️ ABOUT THE SPEAKER

Fabrice Chouraqui has been the CEO of Pharming Group since March 2024. Prior to this, he was a CEO-Partner at the US biotech venture capital firm Flagship Pioneering as well as CEO of the Flagship portfolio company Cellarity.

He also served at Novartis and Bristol-Myers-Squibb for 10 years each, with his career beginning in R&D at pharmaceutical companies that were predecessors to today’s Sanofi.

🔗 LINKS MENTIONED

📜 TRANSCRIPT

Read the full transcript here: https://flot.bio/episode/fabrice-chouraqui-pharming-transgenic-rabbit/

💸 DONATE

We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme

⭐️ SPONSORSHIP

Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!

🫶 FOLLOW US

🙏 LIKE/FOLLOW/REVIEW

Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

🎙️ ABOUT FLOT.BIO

Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.

⏰ TIMESTAMPS

  • - [00:00:00] Intro
  • - [00:02:12] Kicking off at Pharming
  • - [00:04:26] RUCONEST and transgenic rabbits
  • - [00:06:57] Path to profitability
  • - [00:13:43] Encouraging stock price trends
  • - [00:17:39] The protein and small molecules portfolio
  • - [00:28:13] Switching gear to commercialization
  • - [00:33:40] European biotech success stories
  • - [00:39:55] Lessons from Fabrice Chouraqui’s career
  • - [00:47:29] Quick-fire questions
  continue reading

43 episodes

Artwork
iconShare
 
Manage episode 514941053 series 3470295
Content provided by Flot.bio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Flot.bio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

We travel to the offices of Pharming Group in Leiden, the Netherlands, to chat with the newcomer CEO Fabrice Chouraqui.

Fabrice discusses the fascinating history of Pharming, with its first commercial drug RUCONEST produced in the milk of transgenic rabbits. He also talks about the growth of Pharming from a protein therapy-focused biotech into a European multi-asset heavyweight, with a market cap of at least €800 million.

⭐️ ABOUT THE SPEAKER

Fabrice Chouraqui has been the CEO of Pharming Group since March 2024. Prior to this, he was a CEO-Partner at the US biotech venture capital firm Flagship Pioneering as well as CEO of the Flagship portfolio company Cellarity.

He also served at Novartis and Bristol-Myers-Squibb for 10 years each, with his career beginning in R&D at pharmaceutical companies that were predecessors to today’s Sanofi.

🔗 LINKS MENTIONED

📜 TRANSCRIPT

Read the full transcript here: https://flot.bio/episode/fabrice-chouraqui-pharming-transgenic-rabbit/

💸 DONATE

We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme

⭐️ SPONSORSHIP

Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!

🫶 FOLLOW US

🙏 LIKE/FOLLOW/REVIEW

Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

🎙️ ABOUT FLOT.BIO

Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.

⏰ TIMESTAMPS

  • - [00:00:00] Intro
  • - [00:02:12] Kicking off at Pharming
  • - [00:04:26] RUCONEST and transgenic rabbits
  • - [00:06:57] Path to profitability
  • - [00:13:43] Encouraging stock price trends
  • - [00:17:39] The protein and small molecules portfolio
  • - [00:28:13] Switching gear to commercialization
  • - [00:33:40] European biotech success stories
  • - [00:39:55] Lessons from Fabrice Chouraqui’s career
  • - [00:47:29] Quick-fire questions
  continue reading

43 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play